Erythropoiesis-stimulating agent hyporesponsiveness (Review Article)

Nephrology

Volumn 12, Issue 4, 2007, Pages 321-330

  Johnson, David W ^a,d   Pollock, Carol A ^b   Macdougall, Iain C ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Anaemia; Chronic kidney disease; Darbepoetin; Epoetin; Erythropoietin; Iron deficiency

Indexed keywords

ALPHA TOCOPHEROL; ALUMINUM; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; CALCITRIOL; CARNITINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRITIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENTOXIFYLLINE; PLACEBO;

ABDOMINAL PAIN; ALUMINUM OVERLOAD; ANAPHYLAXIS; ARTHRALGIA; ASCORBIC ACID DEFICIENCY; ATHEROSCLEROSIS; BACKACHE; BIOCOMPATIBILITY; BONE MARROW DISEASE; CARNITINE DEFICIENCY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CREATININE CLEARANCE; CYANOCOBALAMIN DEFICIENCY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROPOIESIS; EYE TOXICITY; FOLIC ACID DEFICIENCY; HEART DEATH; HEMOGLOBINOPATHY; HEMOLYSIS; HUMAN; HYPERPARATHYROIDISM; HYPERSPLENISM; HYPOTENSION; INFECTION RISK; INJECTION SITE PAIN; IRON DEFICIENCY; IRON STORAGE; KIDNEY GRAFT; MONOTHERAPY; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHRECTOMY; NUTRITIONAL DEFICIENCY; OXALOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REFRACTORY ANEMIA; RENAL REPLACEMENT THERAPY; RETICULOCYTE COUNT; REVIEW; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; VOMITING;

ALGORITHMS; DECISION TREES; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATINICS; HUMANS; INFLAMMATION; IRON;

EID: 34447542038     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00810.x     Document Type: Review

References (110)

1. Valderrabano F. Erythropoietin in chronic renal failure. Kidney Int. 1996 50 : 1373 91.
2. Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am. J. Kidney Dis. 1999 34 : 1089 95.
3. Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol. Dial. Transplant. 2002 17 (Suppl 1 48 52.
4. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol. Dial. Transplant. 2004 19 (Suppl 2 ii1 47.
5. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am. J. Kidney Dis. 2006 47 : S11 45.
6. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): Current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol. Dial. Transplant. 2005 20 (Suppl 3 iii3 24.
7. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996 50 : 1694 9.
8. Johnson DW, Herzig KA, Gissane R, Campbell SB, Hawley CM, Isbel NM. A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in PD patients. Nephrol. Dial. Transplant. 2001 16 : 1879 84.
9. Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J. Assoc. Physicians India 2003 51 : 170 74.
10. St Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am. J. Kidney Dis. 2005 46 : 650 60.
11. Horl WH, Jacobs C, Macdougall IC. European Survey on Anaemia Management (ESAM). Nephrol. Dial. Transplant. 2000 15 : 43 5.
12. Fishbane S, Lynn RI. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin. Nephrol. 1995 44 : 238 40.
13. Aronoff GR. Safety of intravenous iron in clinical practice: Implications for anemia management protocols. J. Am. Soc. Nephrol. 2004 15 (Suppl 2 S99 106.
14. Devita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, Michelis MF. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin. Nephrol. 2003 60 : 335 40.
15. Besarab A, Amin N, Ahsan M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J. Am. Soc. Nephrol. 2000 11 : 530 38.
16. Roger S. The CARI guidelines. Haematological targets. Iron. Nephrology (Carlton) 2006 11 (Suppl 1 S217 29.
17. Nissenson AR, Charytan C. Controversies in iron management. Kidney Int. Suppl. 2003 87 : S64 71.
18. Fishbane S. Safety issues with iron sucrose. Am. J. Kidney Dis. 2003 41 : 899.
19. Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J. Am. Soc. Nephrol. 2007 18 : 975 84.
20. Saltissi D, Sauvage D, Westhuyzen J. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO). Clin. Nephrol. 1998 49 : 45 8.
21. Macdougall IC, Chandler G, Armstrong A, Breen C, Harchowal J, Cavill J. Characterisation of iron availability from 3 different iron preparations in dialysis patients [Abstract]. J. Am. Soc. Nephrol. 1997 8 : 221.
22. Chandler G. Intravenous iron hydroxy saccharate: Establishing the optimum dose [Abstract]. J. Am. Soc. Nephrol. 2001 8 : 217.
23. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am. J. Kidney Dis. 1996 28 : 529 34.
24. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am. J. Kidney Dis. 1999 33 : 464 70.
25. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981 1 : 1293 4.
26. Drueke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002 106 : 2212 17.
27. Macdougall IC. Strategies for iron supplementation: Oral versus intravenous. Kidney Int. 1999 55 (Suppl 69 S61 6.
28. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J. Am. Soc. Nephrol. 1998 9 : 869 76.
29. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. J. Am. Soc. Nephrol. 2004 15 : 1623 32.
30. Kalantar-Zadeh K, Regidor DL, Mcallister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J. Am. Soc. Nephrol. 2005 16 : 3070 80.
31. Feldman HI, Santanna J, Guo W et al. Iron administration and clinical outcomes in hemodialysis patients. J. Am. Soc. Nephrol. 2002 13 : 734 44.
32. Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999 55 : 1899 911.
33. Panichi V, Migliori M, De Pietro S et al. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 2002 91 : 594 600.
34. Herzig KA, Purdie DM, Brown AM et al. Is C-reactive protein a useful prognostic marker in PD patients? J. Am. Soc. Nephrol. 2001 12 : 814 21.
35. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999 55 : 648 58.
36. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 2000 35 : 469 76.
37. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am. J. Kidney Dis. 1997 29 : 565 8.
38. Tonelli M, Blake PG, Muirhead N. Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J. 2001 47 : 82 5.
39. Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol. Dial. Transplant. 2002 17 (Suppl 1 53 9.
40. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and PD patients. Am. J. Kidney Dis. 1999 33 : 63 72.
41. Park JS, Kim SB. C-reactive protein as a cardiovascular risk factor and its therapeutic implications in end-stage renal disease patients. Nephrology 2003 8 : S40 49.
42. Kaysen GA, Eiserich JP. Characteristics and effects of inflammation in end-stage renal disease. Semin. Dial. 2003 16 : 438 46.
43. Stenvinkel P. Inflammation in end-stage renal failure: Could it be treated? Nephrol. Dial. Transplant. 2002 17 (Suppl 8 33 8.
44. Lopez-Gomez JM, Perez-Flores I, Jofre R et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J. Am. Soc. Nephrol. 2004 15 : 2494 501.
45. Roberts TL, Obrador GT, St Peter WL, Pereira BJ, Collins AJ. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int. 2004 66 : 2429 36.
46. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol. Dial. Transplant. 2001 16 (Suppl 7 25 8.
47. Macdougall IC, Cooper AC. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur. J. Clin. Invest. 2005 35 (Suppl 3 32 5.
48. Malyszko J, Malyszko JS, Hryszko T, Pawlak K, Mysliwiec M. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients? Am. J. Nephrol. 2005 25 : 586 90.
49. Hsu PY, Lin CL, Yu CC et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - A prospective cross-over study. J. Nephrol. 2004 17 : 693 700.
50. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol. Dial. Transplant. 2000 15 : 1207 11.
51. Ayus JC, Achinger SG. At the peril of dialysis patients: Ignoring the failed transplant. Semin. Dial. 2005 18 : 180 84.
52. Attallah N, Osman-Malik Y, Frinak S, Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am. J. Kidney Dis. 2006 47 : 644 54.
53. Kobayashi S, Moriya H, Aso K, Ohtake T. Vitamin E-bonded hemodialyzer improves atherosclerosis associated with a rheological improvement of circulating red blood cells. Kidney Int. 2003 63 : 1881 7.
54. Sirken G, Kung SC, Raja R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J. 2003 49 : 422 5.
55. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin- resistant anemia in renal failure. J. Am. Soc. Nephrol. 2004 15 : 1877 82.
56. Navarro JF, Mora C, Garcia J et al. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scand. J. Urol. Nephrol. 1999 33 : 121 5.
57. Kobayashi H, Ono T, Yamamoto N. Removal of high molecular weight substances with large porse size membrane (BK-F). Kidney Dial. 1993 34 : 154 7.
58. Kawano Y, Takaue Y, Kuroda Y, Minkuchi J, Kawashima S. Effect on alleviation of renal anemia by haemodialysis using the high-flux dialyzer (BK-F). Kidney Dial. 1994 34 : 200 203.
59. Locatelli F, Del Vecchio L. Dialysis adequacy and response to erythropoietic agents: What is the evidence base? Nephrol. Dial. Transplant. 2003 18 (Suppl 8 viii29 35.
60. Locatelli F, Andrulli S, Pecchini F et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol. Dial. Transplant. 2000 15 : 1399 409.
61. Locatelli F. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J. Med. 2003 348 : 1491 4.
62. Niwa T, Yazawa T, Kodama T, Uehara Y, Maeda K, Yamada K. Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory PD. Nephron 1990 56 : 241 5.
63. Mcgonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int. 1984 25 : 437 44.
64. Opatrny K Reischig T, Vienken J et al. Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis. Artif. Organs 2002 26 : 181 8.
65. Keven K, Kutlay S, Nergizoglu G, Erturk S. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am. J. Kidney Dis. 2003 41 : 1233 9.
66. Chan D, Irish A, Dogra G. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Nephrology (Carlton) 2005 10 : 336 40.
67. Yang CC, Hsu SP, Wu MS, Hsu SM, Chien CT. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int. 2006 69 : 706 14.
68. Bernardini J, Nagy M, Piraino B. Pattern of noncompliance with dialysis exchanges in PD patients. Am. J. Kidney Dis. 2000 35 : 1104 10.
69. Wazny LD, Stojimirovic BB, Heidenheim P, Blake PG. Factors influencing erythropoietin compliance in PD patients. Am. J. Kidney Dis. 2002 40 : 623 8.
70. Kaveh K, Kimmel PL. Compliance in hemodialysis patients: Multidimensional measures in search of a gold standard. Am. J. Kidney Dis. 2001 37 : 244 66.
71. Santiago GC, Rao TK, Laird NM. Effect of dialysis therapy on the hematopoietic system: The National Cooperative Dialysis Study. Kidney Int. Suppl. 1983 : S95 100.
72. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N. Engl. J. Med. 1996 334 : 420 25.
73. Movilli E, Cancarini GC, Zani R, Camerini C, Sandrini M, Maiorca R. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol. Dial. Transplant. 2001 16 : 111 14.
74. Klarenbach S, Heidenheim AP, Leitch R, Lindsay RM. Reduced requirement for erythropoietin with quotidian hemodialysis therapy. ASAIO J. 2002 48 : 57 61.
75. Akmal M, Telfer N, Ansari AN, Massry SG. Erythrocyte survival in chronic renal failure. Role of secondary hyperparathyroidism. J. Clin. Invest. 1985 76 : 1695 8.
76. Kwack C, Balakrishnan VS. Managing erythropoietin hyporesponsiveness. Semin. Dial. 2006 19 : 146 51.
77. Mandolfo S, Malberti F, Farina M et al. Parathyroidectomy and response to erythropoietin therapy in anaemic patients with chronic renal failure. Nephrol. Dial. Transplant. 1998 13 : 2708 9.
78. Lee CT, Chou FF, Chang HW et al. Effects of parathyroidectomy on iron homeostasis and erythropoiesis in hemodialysis patients with severe hyperparathyroidism. Blood Purif. 2003 21 : 369 75.
79. Neves PL, Trivino J, Casaubon F et al. Elderly patients on chronic hemodialysis with hyperparathyroidism: Increase of hemoglobin level after intravenous calcitriol. Int. Urol. Nephrol. 2006 38 : 175 7.
80. Zachee P, Chew SL, Daelemans R, Lins RL. Erythropoietin resistance due to vitamin B12 deficiency. Case report and retrospective analysis of B12 levels after erythropoietin treatment. Am. J. Nephrol. 1992 12 : 188 91.
81. Suega K, Bakta M, Dharmayudha TG, Lukman JS, Suwitra K. Profile of anemia in chronic renal failure patients: Comparison between predialyzed and dialyzed patients at the Division of Nephrology, Department of Internal Medicine, Sanglah Hospital, Denpasar, Bali, Indonesia. Acta Med. Indones. 2005 37 : 190 94.
82. Schiffl H, Lang SM. Folic acid deficiency modifies the haematopoietic response to recombinant human erythropoietin in maintenance dialysis patients. Nephrol. Dial. Transplant. 2006 21 : 133 7.
83. Bamgbola OF, Kaskel F. Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis. Pediatr. Nephrol. 2005 20 : 1622 9.
84. Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol. Dial. Transplant. 1995 10 (Suppl 6 44 7.
85. Schreiber BD. Debate forum: Levocarnitine therapy is rational and justified in selected dialysis patients. Blood Purif. 2006 24 : 128 39.
86. Kooistra MP, Struyvenberg A, van Es A. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels. Nephron 1991 57 : 127 8.
87. Matsumura M, Hatakeyama S, Koni I, Mabuchi H, Muramoto H. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron 1996 72 : 574 8.
88. Handelman GJ. Debate forum: Carnitine supplements have not been demonstrated as effective in patients on long-term dialysis therapy. Blood Purif. 2006 24 : 140 42.
89. Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of 1-carnitine supplementation in maintenance hemodialysis patients: A systematic review. J. Am. Soc. Nephrol. 2002 13 : 708 14.
90. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am. J. Kidney Dis. 2001 37 : S182 238.
91. Azizi M, Rousseau A, Ezan E et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J. Clin. Invest. 1996 97 : 839 44.
92. Casadevall N. Cellular mechanism of resistance to erythropoietin. Nephrol. Dial. Transplant. 1995 10 (Suppl 6 27 30.
93. Kausz AT, Antonsen JE, Hercz G et al. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am. J. Kidney Dis. 1999 34 : 688 93.
94. Milliner DS, Nebeker HG, Ott SM et al. Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann. Intern. Med. 1984 101 : 775 9.
95. Yaqoob M, Ahmad R, Mcclelland P et al. Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy. Postgrad. Med. J. 1993 69 : 124 8.
96. Von Bonsdorff M, Sipila R, Pitkanen E. Correction of haemodialysis- associated anaemia by deferoxamine. Effects on serum aluminum and iron overload. Scand. J. Urol. Nephrol. Suppl. 1990 131 : 49 54.
97. Roger SD, Stewart JH, Harris DC. Desferrioxamine enhances the haemopoietic response to erythropoietin, but adverse events are common. Nephron 1991 58 : 33 6.
98. Mittelman M. The implications of anemia in multiple myeloma. Clin. Lymphoma 2003 4 (Suppl 1 S23 9.
99. Maisnar V, Chroust K. Treatment of associated anemia in different hematological disorders with epoetin alpha. Neoplasma 2004 51 : 379 84.
100. Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin. Oncol. 1992 19 : 29 35.
101. Ludwig H, Rai K, Blade J et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: Epoetin treatment recommendations. Hematol. J. 2002 3 : 121 30.
102. Baz R, Walker E, Choueiri TK et al. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol. 2006 117 : 162 7.
103. Rossert J. Erythropoietin-induced, antibody-mediated pure red cell aplasia. Eur. J. Clin. Invest. 2005 35 (Suppl 3 95 9.
104. Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: A retrospective study. Lancet 2004 363 : 1768 71.
105. Woodburn KW, Winslow S, Leuther KK. Hematide, a Peptidic Erythropoiesis Stimulating Agent that Corrects Anaemia Induced by Partial Nephrectomy and Erythropoietin-specific Antibodies in Rats. European Haematology Association Meeting, Stockholm, 2005.
106. Gallucci MT, Lubrano R, Meloni C et al. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients. Clin. Nephrol. 1999 52 : 239 45.
107. Tomson CR, Edmunds ME, Chambers K, Bricknell S, Feehally J, Walls J. Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol. Dial. Transplant. 1992 7 : 817 21.
108. Breen CP, Macdougall IC. Improvement of erythropoietin-resistant anaemia after renal transplantation in patients with homozygous sickle-cell disease. Nephrol. Dial. Transplant. 1998 13 : 2949 52.
109. Di Iorio B, Guastaferro P, Bellizzi V. Relationship between resistance to erythropoietin and high anomalous hemoglobin levels in hemodialysis patients with beta-thalassemia minor. Blood Purif. 2003 21 : 376 80.
110. Leighton JA, Goldstein J, Hirota W et al. Obscure gastrointestinal bleeding. Gastrointest. Endosc. 2003 58 : 650 55.